ANXA5 and ovarian carcinoma: In the present study, we first investigated GP‐2250's direct inhibitory effect on ovarian cancer cell proliferation in a series of in vitro experiments, including MTT and BrdU assays, trypan blue exclusion, and an annexin V/propidium iodide (PI) assay.